Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Raised by Centaurus Financial Inc.

Centaurus Financial Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 27.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,891 shares of the company’s stock after buying an additional 3,876 shares during the quarter. Centaurus Financial Inc.’s holdings in Teva Pharmaceutical Industries were worth $322,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock worth $11,648,000 after acquiring an additional 28,071 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $166,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $30,000. PEAK6 Investments LLC raised its position in shares of Teva Pharmaceutical Industries by 105.7% in the first quarter. PEAK6 Investments LLC now owns 54,868 shares of the company’s stock valued at $774,000 after purchasing an additional 1,025,261 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Teva Pharmaceutical Industries by 21.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 201,849 shares of the company’s stock worth $2,849,000 after buying an additional 36,295 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.59 on Wednesday. The firm has a market capitalization of $18.79 billion, a price-to-earnings ratio of -19.52, a PEG ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a one year low of $9.35 and a one year high of $19.31. The business has a fifty day simple moving average of $17.62 and a 200 day simple moving average of $17.36. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Analyst Ratings Changes

TEVA has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.